Ruurd M van Elburg1,2, Manon J N L Benders3,4, Lisa M Hortensius1,5, Edith H van den Hooven6, Jeroen Dudink1,5, Maria Luisa Tataranno1,5. 1. Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. 2. Emma Children's Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Department of Neonatology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. m.benders@umcutrecht.nl. 4. University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands. m.benders@umcutrecht.nl. 5. University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands. 6. Danone Nutricia Research, Utrecht, The Netherlands.
Abstract
BACKGROUND: The gut microbiota and the brain are connected through different mechanisms. Bacterial colonisation of the gut plays a substantial role in normal brain development, providing opportunities for nutritional neuroprotective interventions that target the gut microbiome. Preterm infants are at risk for brain injury, especially white matter injury, mediated by inflammation and infection. Probiotics, prebiotics and L-glutamine are nutritional components that have individually already demonstrated beneficial effects in preterm infants, mostly by reducing infections or modulating the inflammatory response. The NutriBrain study aims to evaluate the benefits of a combination of probiotics, prebiotics and L-glutamine on white matter microstructure integrity (i.e., development of white matter tracts) at term equivalent age in very and extremely preterm born infants. METHODS: This study is a double-blind, randomised, controlled, parallel-group, single-center study. Eighty-eight infants born between 24 + 0 and < 30 + 0 weeks gestational age and less than 72 h old will be randomised after parental informed consent to receive either active study product or placebo. Active study product consists of a combination of Bifidobacterium breve M-16V, short-chain galacto-oligosaccharides, long-chain fructo-oligosaccharides and L-glutamine and will be given enterally in addition to regular infant feeding from 48 to 72 h after birth until 36 weeks postmenstrual age. The primary study outcome of white matter microstructure integrity will be measured as fractional anisotropy, assessed using magnetic resonance diffusion tensor imaging at term equivalent age and analysed using Tract-Based Spatial Statistics. Secondary outcomes are white matter injury, brain tissue volumes and cortical morphology, serious neonatal infections, serum inflammatory markers and neurodevelopmental outcome. DISCUSSION: This study will be the first to evaluate the effect of a combination of probiotics, prebiotics and L-glutamine on brain development in preterm infants. It may give new insights in the development and function of the gut microbiota and immune system in relation to brain development and provide a new, safe treatment possibility to improve brain development in the care for preterm infants. TRIAL REGISTRATION: ISRCTN, ISRCTN96620855 . Date assigned: 10/10/2017.
RCT Entities:
BACKGROUND: The gut microbiota and the brain are connected through different mechanisms. Bacterial colonisation of the gut plays a substantial role in normal brain development, providing opportunities for nutritional neuroprotective interventions that target the gut microbiome. Preterm infants are at risk for brain injury, especially white matter injury, mediated by inflammation and infection. Probiotics, prebiotics and L-glutamine are nutritional components that have individually already demonstrated beneficial effects in preterm infants, mostly by reducing infections or modulating the inflammatory response. The NutriBrain study aims to evaluate the benefits of a combination of probiotics, prebiotics and L-glutamine on white matter microstructure integrity (i.e., development of white matter tracts) at term equivalent age in very and extremely preterm born infants. METHODS: This study is a double-blind, randomised, controlled, parallel-group, single-center study. Eighty-eight infants born between 24 + 0 and < 30 + 0 weeks gestational age and less than 72 h old will be randomised after parental informed consent to receive either active study product or placebo. Active study product consists of a combination of Bifidobacterium breve M-16V, short-chain galacto-oligosaccharides, long-chain fructo-oligosaccharides and L-glutamine and will be given enterally in addition to regular infant feeding from 48 to 72 h after birth until 36 weeks postmenstrual age. The primary study outcome of white matter microstructure integrity will be measured as fractional anisotropy, assessed using magnetic resonance diffusion tensor imaging at term equivalent age and analysed using Tract-Based Spatial Statistics. Secondary outcomes are white matter injury, brain tissue volumes and cortical morphology, serious neonatal infections, serum inflammatory markers and neurodevelopmental outcome. DISCUSSION: This study will be the first to evaluate the effect of a combination of probiotics, prebiotics and L-glutamine on brain development in preterm infants. It may give new insights in the development and function of the gut microbiota and immune system in relation to brain development and provide a new, safe treatment possibility to improve brain development in the care for preterm infants. TRIAL REGISTRATION: ISRCTN, ISRCTN96620855 . Date assigned: 10/10/2017.
Authors: Rochellys Diaz Heijtz; Shugui Wang; Farhana Anuar; Yu Qian; Britta Björkholm; Annika Samuelsson; Martin L Hibberd; Hans Forssberg; Sven Pettersson Journal: Proc Natl Acad Sci U S A Date: 2011-01-31 Impact factor: 11.205
Authors: Javier A Bravo; Paul Forsythe; Marianne V Chew; Emily Escaravage; Hélène M Savignac; Timothy G Dinan; John Bienenstock; John F Cryan Journal: Proc Natl Acad Sci U S A Date: 2011-08-29 Impact factor: 11.205
Authors: Gareth Ball; Serena J Counsell; Mustafa Anjari; Nazakat Merchant; Tomoki Arichi; Valentina Doria; Mary A Rutherford; A David Edwards; Daniel Rueckert; James P Boardman Journal: Neuroimage Date: 2010-05-25 Impact factor: 6.556
Authors: Elizabeth B Isaacs; David G Gadian; Stuart Sabatini; Wui K Chong; Brian T Quinn; Bruce R Fischl; Alan Lucas Journal: Pediatr Res Date: 2008-03 Impact factor: 3.756
Authors: Jorrit F de Kieviet; Jaap Oosterlaan; R Jeroen Vermeulen; Petra J W Pouwels; Harrie N Lafeber; Ruurd M van Elburg Journal: Pediatrics Date: 2012-10-15 Impact factor: 7.124